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Abstract
Background: There is a relative lack of recent information about late post kidney transplantation anaemia (PTA),
especially in the developing countries; data are scarce about the prevalence and risk factors of PTA. Sudan was a
leading country in Africa and Arab world in kidney transplantation. The first kidney transplantation in Sudan was in
1973.
Methods: This is a cross-sectional hospital analytic study enrolling all kidney transplanted recipients following in
the transplant referral clinics at Ahmed Gassim, Selma and Ibn Sina Hospitals, Khartoum/Sudan, in the period from
1/8/2010 to 1/9/2010, clinical and laboratory data were obtained from 114 patients, anaemia was defined as Hb
levels of < 13 g/dl for male patients and < 12 g/dl for female patients, exclusion criteria were pregnancy, below 18
years old patients, multiple organ transplantation, and patients with less than one year from the transplantation.
Results: The study showed that 39.5% of the patients were anaemic. Univariate analysis showed that late PTA is
significantly associated with not using Erythropoietin (EPO) in the pre-transplant period (p = < 0.001), history of
rejection (p = 0.003), longer time from transplantation (p = 0.015), and eGFR (p < 0.0001). Multivariate analysis
showed that eGFR (p = < 0.001) and not use of EPO in the pre transplant period (p < 0.001) are strong predictors
of PTA. The use of Angiotensin converting enzyme inhibitors/Angiotensin receptors blockers (ACEI/ARB),
immunosuppressive treatments, presence or absence of co-morbidities, donor type and donor age are not
significantly associated with late PTA.
Conclusion: The study concluded that late PTA is common and under recognized. Risk factors for late PTA include
renal dysfunction, history of rejection, longer duration of transplantation and not using EPO in the pre-transplant
period. Renal dysfunction and not using EPO in the pre-transplant period are major predictors of late PTA.
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Background
Anaemia in End Stage Renal Failure (ESRF) is mainly
due to loss of the endocrine function of the kidneys that
lead to deficiency of erythropoietin (EPO) and develop-
ment of anaemia. Many studies pointed out the preva-
lence of Post transplant Anaemia (PTA) in developed
countries, a Japanese study concluded that the preva-
lence of PTA is 20% [1], a big multicenter study
conducted in 72 centers in 16 European countries
[Transplant European Survey on Anaemia Management
(TRESAM)] concluded that the prevalence of PTA was
38.6% [2]. In a published British study, the prevalence of
anaemia was 53% at 12 months from the kidney trans-
plantation [3]. A Turkish study concluded that preva-
lence of PTA was 49.3% [4], in Austria PTA was present
in 39.7% [5]. Among Hungarians, PTA was 33.8% [6].
Renal dysfunction is strongly associated with develop-
ment of PTA [2,7-18] and considered as a major risk
factor, other risk factors like rejection [9,19,20], recent
infections [21-24], longer duration from transplantation
[7], immunosuppressive treatments [3,25-32], use of
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receptors blockers (ACEI/ARB) [2,12,13,33,34], low
serum albumin [4], protein energy waste syndrome [35],
and old age of the kidney donor [2] are all considered
as risk factors for development of PTA.
Our aim in this study is to identify the prevalence of
late PTA (> 1 year post transplant) and the risk factors
of late PTA among adult Sudanese kidney recipients.
Methods
Study population & Data collection
T h i ss t u d yi sac r o s ss e c t i o n a lh o s p i t a lb a s ea n a l y t i c
study. The subjects of the study are all kidney trans-
planted recipients following in the transplant referral
clinics at Ahmed Gassim, Selma & Ibn Sina Hospitals,
Khartoum/Sudan. All patients attending the transplant
referral clinics between (1/8/2010 - 1/9/2010) were
interviewed by questionnaire focusing on personal and
clinical data exploring (time on dialysis, receiving EPO
treatment during dialysis, period of transplantation,
donor age, immunosuppressive regimen, The use of
ACEI/ARB, history of rejection, and presence or absence
of co-morbidities) with a review of their medical files.
All laboratory investigations conducted at the time of
the visit such as (complete blood count, peripheral
blood picture, and renal functions) were reported. Esti-
mated Glomerular Filtration rate (eGFR) was calculated
using the abbreviated modification of diet in renal dis-
ease (MDRD) study formula [36]. The research was in
compliance of the declaration of Helsinki and approved
by ethics and research committees in the local hospitals,
an informed consent was obtained from each patient
participated in the study
Haemoglobin target
Anaemia was defined as Hb levels of < 13 g/dl for male
patients and < 12 g/dl for female patients this targets
were selected based on the WHO guidelines & the
American Society of Transplantation [37].
Inclusion & exclusion criteria
We included all kidney transplant recipients who
received a kidney transplant and attended the referral
clinic at Ahmed Gassim, Selma and Ibn Sina Hospitals
between 1/8 -1/9/2010. The exclusion criteria were
Pregnancy, below 18 years old patients, multiple organ
transplantation and patients with less than 1 year from
the transplantation.
Statistical analysis
Categorical variables between the anaemic and non
anaemic patients were compared using X
2 test, con-
tinues variables between the anaemic and non anaemic
patients were compared using Student T-test.
Multivariate linear regression analysis used to identify
the predictors of PTA. Statistical analysis conducted
using SPSS 18 software package (SPSS Inc, Chicago, IL,
USA) and P value < 0.05 were considered significant.
Results
The characteristics of the study population are shown in
Table 1. Our result showed that the prevalence of late
PTA was 39.5% of all Sudanese kidneys transplanted
patients. Prevalence of anaemia in Ibn Sina centre was
38.7%, Selma centre was 38.5% and Ahmed Gassim cen-
tre was 40%
A univariate analysis of risk factors associated with
late PTA showed that anaemia is significantly associated
with not using EPO in pre-transplant period (p < 0.001),
History of rejection was also associated with PTA (p =
0.003), eGFR (p < 0.0001) and long period from trans-
plantation (p = 0.015). No significant relation was found
between anaemia and age, time on dialysis, donor age,
immunosuppressive treatments, presence or absence of
co-morbidities, ACEI/ARB and gender (Table 2).
Multivariate analysis conducted by linear regression
analysis for risk factors of late PTA, using haemoglobin
as dependant variable, in the linear regression model (r=
0.626, p = < 0.0001) eGFR (p < 0.0001) and not using
Table 1 The characteristics of the study population
Recipient gender
a Male 78 (68.4%)
Female 36 (31.6%)
Recipient age
b 42.4 ± 12.66
Occupation
a Unemployed 81 (71.1%)
Non professional 16 (14%)
Professional 17 (14.9%)
Donor type
a Living related donor: 99
(86.8%)
Living unrelated: 15 (13.2%)
History of acute rejection
a Yes 13 (11.4%) No 101 (88.6%)
Donor age (years)
b 28.9 ± 7.6
Use of EPO pre-transplant
a Yes 64 (56.1%) No 50 (43.9%)
Use of Mycofenolate mofetil
a Yes 31 (27.2%) No 83(72.8%)
Use of Azathioprine
a Yes 80 (70.2%) No 34 (29.8%)
Use of Cyclosporine
a Yes 45 (39.5%) No 69 (60.5%)
Use of Tacrolimus
a Yes 65 (57%) No 49 (43%)
Use of ACEI/ARB
a Yes 23 (20.2%) No 91 (79.8%)
Co-morbidities Yes 9 (7.9%) No 105 (92%)
Time on Dialysis (months)
b 14.6 ± 13
Period of kidney transplantation
(months)
b
49 ± 42.26
Hb g/dl
b 12.7 ± 1.96
Creatinine mg/dl
b 1.4 ± 0.88
Urea mg/dl
b 39.17 ± 19.5
eGFR ml/min/1.73
2b 81.6 ± 34.3
a Number (percentage),
b Mean ± SD
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cantly predict anaemia among kidney recipients (Table 3)
Discussion
Prevalence of Late PTA
Published literature on PTA is limited, especially in
developing countries, this is due to lack of transplanta-
tion facilities which lead to deficiency on PTA published
data, this study is the first Sudanese study on prevalence
and risk factors of late PTA. Our result showed that
39.5% of kidney transplanted patients have anaemia.
This high prevalence indicates the severity of this pro-
blem among Sudanese renal transplanted population;
our result is higher than many of the published litera-
ture in the developed countries. Prevalence of PTA in
Japan is 20% [1]. In other American study it was 26% in
5 years post transplant [7]. In the European TRESAM
study it was 38% [2]. In Austria, PTA was present in
39.7% [5]. Among Hungarians, PTA was 33.8% [6]. In
other hand data published from Asia and South America
showed higher prevalence of PTA, in Turkey PTA was
present among 49.3% of transplanted patients [4], PTA
in Argentina was 42.2% [38].
The characteristics of the study population
In our study, we reviewed 114 patients, 68% were males,
Live related donors constitute 86.6% of the donor type
with no cadaveric donors in our study population; this
is very different from the other major published litera-
ture from the developed countries where cadaveric
donors are the major donor type in kidney transplanta-
tion. 43.9% of this study population didn’t receive EPO
during dialysis because of financial reasons which
reflects poor management of anaemia among our
patients in the pre-transplant period. The mean age in
this study was 42 years. Only 9 patients have co-morbid-
ities mainly (Liver diseases, Diabetes mellitus and Heart
diseases). Despite that renal transplantation improves
the quality of life of the patients; unemployment rate is
high among kidney recipients 71.1%
Risk factors for PTA
After univariate analysis of the variables, history of rejec-
tion was associated with anaemia (p = 0.003), this result
agrees with many of published articles which stated that
rejection is a leading cause for anaemia [9,19,20].
Renal dysfunction was strongly associated with anae-
mia; in our study, anaemic patients have mean of eGFR
Table 2 Risk factors of post transplant anaemia
Anaemic group
N (45)
Non anaemic group
N (69)
P value
Age
b 42.9 ± 12. 9 42 ± 12.7 0.7
Gender (M/F)
a 31/14 47/22 0.93
Use of (EPO) pre transplant
a 12 (18.8%) 52 (81.3%) < 0.0001
Donor type
a
Living related
38 (38.4%) 61 (61.6%) 0.54
Living unrelated
a 8 (53.3%) 7 (46.7%)
History of rejection
a 10 (76.9%) 3 (23.1%) 0.003
Use of Mycofenolate mofetil
a 10 (32.3%) 21 (67.7%) 0.33
Use of Azathioprine
a 33 (41.2%) 47 (58.8%) 0.55
Use of Cyclosporine
a 22 (48.9%) 23(51.1)% 0.09
Use of Tacrolimus
a 21(32.3%) 44 (67.7%) 0.07
Use of ACEI/ARB
a 8(34.8%) 15(65.2%) 0.6
Presence of Co-Morbidities 2(22.2%) 7 (77.8) 0.27
Time on dialysis (months)
b 12.9 ± 11.6 15.7 ± 13.8 0.26
Time since transplantation (months)
b 62.1 ± 51.5 40.5 ± 33.02 0.015
Donor age (years)
b 29.3 ± 7 28.5 ± 8 0.6
eGFR (ml/min/1.73
2 56.8 ± 20.7 97.7 ± 31.8 < 0.0001
a Number (percentage),
b Mean ± SD
Table 3 Liner regression model of serum haemoglobin as
dependant variable (r = 0.626, p = < 0.0001)
Variable b t P value
Age -0.008 -0.097 0.923
Gender 0.058 0.731 0.466
eGFR 0.381 4.563 < 0.0001
Presence or absence of Co-morbidities -0.064 -0.822 0.431
Time since transplantation -0.031 - 0385 0.701
History of rejection -0.123 -1.608 0.111
Use of EPO 0.376 4.736 < 0.0001
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2 (p = < 0.0001), this result is going
with the majority of published literature on PTA sug-
gesting renal dysfunction as major cause of PTA
[2,7-18].
Patients with longer duration of transplantation have
more tendency to develop late PTA (p = 0.015), this is
agrees with many literature which pointed out the
increase prevalence of anaemia in the late post-trans-
plant period in comparison with early post-transplant
period [7], this is also can be explained by the fact that
chronic allograft nephropathy can occur after long time
from transplantation and that may lead to development
of PTA.
In this study not using of EPO before transplantation
was a major risk factor for PTA (p < 0.0001), so patients
may still have significant anaemia at time of transplanta-
tion. Use of EPO pre transplant is associated with better
5 year graft survival and reduce frequency of rejection
[39], concerning the level of EPO in the post transplant
period, in a study compared two groups (anaemic &
non-anaemic) of renal transplant recipients with normal
renal functions, EPO deficiency and resistance play a
causative role for PTA [40], however in other study no
relation was found between administration of the EPO
and anaemia, the same result favoring use of EPO only
on high risk patients [41].
Multivariate analysis showed that renal dysfunction
and not using EPO before transplantation were major
predictors for PTA.
In this result, immunosuppressive treatment was not
associated with anaemia this is contradicting with the
majority of the literature which stating the strong rela-
tionship [3,25-32], however another study found no rela-
tion between anaemia and some combinations of
immunosuppressive treatments [2] and perhaps live
related transplantation needing less immunosuppressive
treatments may be the curl print point.
In this study there was no relation between ACEI/ARB
and late PTA, the literature concerning that is contro-
versial with some favoring the link between PTA and
ACEI/ARB [2,12,13,33,34] and other articles denied the
relationship [15,17].
Our study had many limitations that need to be recog-
nized, we didn’t have data on iron stores and serum
albumin this is mainly due to lack of financial recourses,
medical data about the exact nature and details of co-
morbidities was difficult to obtain, so we just asked our
patients about nature and presence or absence of co
morbidities. Data about numbers and treatment of rejec-
tion and history of blood transfusions was not collected.
Conclusion
The study concluded that late PTA is common and
under recognized. Risk factors for late PTA include
renal dysfunction, history of rejection, longer duration
of transplantation and not using EPO in the pre-trans-
plant period. Renal dysfunction and not using EPO in
the pre-transplant period are major predictors of PTA.
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